Table 3 Administration of induction chemotherapy
Induction chemotherapy parameter | Number of patients (%), N = 18 | |||||
|---|---|---|---|---|---|---|
Dose level | ||||||
0 | 12 | (67) | ||||
-1 | 6 | (33) | ||||
DLT | 8 | (44) | ||||
in dose level 0 | 7 | (38) | ||||
in dose level -1 | 1 | (6) | ||||
Number of doses* of TPF (Median, range) | 6, 1 - 6 | |||||
Number of patients completed maximal | level 0 | level -1 | all patients | |||
number of cycles induction chemotherapy | N = 12 | N = 6 | N = 18 | |||
3 cycles | 7 | (58) | 5 | (83) | 12 | (67) |
2 cycles | 7 | (58) | 5 | (83) | 12 | (67) |
1 cycle** | 5 | (42) | 1 | (17) | 6 | (33) |
Dose intensity***, overall (Median, range) | ||||||
Docetaxel | 333.8, 78.2 – 474 | |||||
Cisplatin | 375.3, 78.2 – 474 | |||||
5-Fluorouracil | 10020, 3211 - 11851 | |||||
Dose density**** per cycle | Week 1 | Week 2 | ||||
Dose density, cycle 1 (Median, range) | ||||||
Docetaxel | 72.6, 45.2 – 80.5 | 71.3, 45 – 80 | ||||
Cisplatin | 73.96, 60.3 – 80.5 | 73, 45.3 – 80 | ||||
5-Fluorouracil | 3708, 3016 - 4025 | 3680, 3002 - 4000 | ||||
Dose density, cycle 2 (Median, range) | ||||||
Docetaxel | 65.9, 45 – 79.2 | 65.8, 44.8 – 79.2 | ||||
Cisplatin | 70.8, 44.9 – 79.2 | 71, 44.8 – 79.2 | ||||
5-Fluorouracil | 3572, 2990 - 3960 | 3550, 2992 – 3960 | ||||
Dose density, cycle 3 (Median, range) | ||||||
Docetaxel | 66.2, 46.9 – 78.6 | 60.1, 36.1 – 78.6 | ||||
Cisplatin | 71.3, 44.9 – 78.6 | 69.5, 45.1 – 78.6 | ||||
5-Fluorouracil | 3546, 2392 - 3931 | 3482, 2404 - 3931 | ||||
Number of patients with dose reductions | 4 | (22) | ||||